A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 9, Issue 7, Pages 693-704
Publisher
Future Science, LTD
Online
2017-05-16
DOI
10.4155/fmc-2016-0222
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC
- (2017) Benjamin Solomon Journal of Thoracic Oncology
- EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
- (2016) Katherine R. Amato et al. CANCER RESEARCH
- Abstract 1068: The promise of miR-205 in HER2+ breast cancer: predicting response to Trastuzumab and overcoming resistance
- (2016) Claudia Piovan et al. CANCER RESEARCH
- A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
- (2016) P. C. Rodriguez et al. CLINICAL CANCER RESEARCH
- The Membrane Mimetic Affects the Spatial Structure and Mobility of EGFR Transmembrane and Juxtamembrane Domains
- (2015) Konstantin S. Mineev et al. BIOCHEMISTRY
- Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
- (2015) Said A Khelwatty et al. BRITISH JOURNAL OF CANCER
- Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients
- (2015) Y. Wang et al. Clinical & Translational Oncology
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
- (2015) Julian Engel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
- (2015) Ricard Mesía et al. LANCET ONCOLOGY
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
- (2015) Jin Ho Baek et al. LUNG CANCER
- Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma
- (2015) Arun Khattri et al. ORAL ONCOLOGY
- Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
- (2015) Jianchun Duan et al. Thoracic Cancer
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling In Vitro and In Vivo
- (2015) Saghir Akhtar et al. PLoS One
- Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX
- (2015) Marissa V Powers et al. Oncotarget
- Hsp90 Chaperone Inhibitor 17-AAG Attenuates A -Induced Synaptic Toxicity and Memory Impairment
- (2014) Y. Chen et al. JOURNAL OF NEUROSCIENCE
- Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790to Methionine790(T790M) Mutants
- (2013) Tianfeng Xu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Architecture and Membrane Interactions of the EGF Receptor
- (2013) Anton Arkhipov et al. CELL
- Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor
- (2013) Nicholas F. Endres et al. CELL
- Ins and Outs of Kinase DFG Motifs
- (2013) Daniel K. Treiber et al. CHEMISTRY & BIOLOGY
- Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties
- (2013) Shilin Xu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110
- (2013) A. Schulte et al. NEURO-ONCOLOGY
- Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
- (2013) M. Red Brewer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transitions to catalytically inactive conformations in EGFR kinase
- (2013) Y. Shan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Structural investigation of deleterious non-synonymous SNPs of EGFR gene
- (2013) Dhwani Raghav et al. Interdisciplinary Sciences-Computational Life Sciences
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
- (2012) S Yoshikawa et al. ONCOGENE
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
- (2011) Jean-Charles Soria et al. CANCER TREATMENT REVIEWS
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
- (2011) M. He et al. CLINICAL CANCER RESEARCH
- EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity
- (2010) Hu Zhu et al. CANCER LETTERS
- Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor
- (2010) C. Lu et al. MOLECULAR AND CELLULAR BIOLOGY
- Spatial control of EGF receptor activation by reversible dimerization on living cells
- (2010) Inhee Chung et al. NATURE
- EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism
- (2010) G Pines et al. ONCOGENE
- Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics
- (2009) Judith Jeuken et al. BRAIN PATHOLOGY
- EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma
- (2009) B. Mukherjee et al. CANCER RESEARCH
- The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
- (2009) Monica Red Brewer et al. MOLECULAR CELL
- EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor
- (2009) J-J Li et al. ONCOGENE
- Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
- (2009) Haihao Zhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic EGFR Signaling Networks in Glioma
- (2009) P. H. Huang et al. Science Signaling
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
- (2008) Judith Schmiedel et al. CANCER CELL
- Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
- (2008) T. Shimamura et al. CANCER RESEARCH
- Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
- (2008) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State
- (2008) Eduard V. Bocharov et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started